ABSTRACT
Congenital combined bleeding disorders (CBDs) are extremely rare disorders which mainly occur in regions with a high rate of consanguineous marriage. These disorders can present with a variety of symptoms ranging from mucocutaneous bleeding to life-threatening episodes. This study aims to evaluate the prevalence and clinical course of Iranian patients with congenital CBDs. This study is conducted on 450 patients with CBDs who were referred to the Iranian Comprehensive Hemophilia Care Center (ICHCC) between 2010 and 2020. All these patients were diagnosed through evaluation of past medical history and coagulation laboratory investigation. Out of 450 patients, 33 were entered in this study. Having excluded cases with factor (F) V and FVIII deficiency, as well as those with hereditary combined Vitamin K dependent clotting factor deficiency (VKCFD), We found the most common CBDs to be FV-FVII deficiency (n: 6, 18.1%), together with FVII and FX deficiency (n: 6, 18.1%). The most common reason for referral of these patients to ICHCC was postoperative bleeding (14.3%). The mean of The International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT) and condensed MCMDM-1VWD bleeding assessment tool were 9.6 ± 4.79 and 9.1 ± 4.87, respectively (P < 0.005). In 10 females of reproductive age, the mean of Pictorial Bleeding Assessment Chart (PBAC) score was 649.3 ± 554. Among all patients, 23 (69.7%) received on-demand replacement therapy, whereas 5 patients (15.1%) received prophylaxis. In Iran, the coinheritance of bleeding disorders is surprisingly higher than expected. Moreover, patients with congenital CBDs may experience serious bleeding manifestations.
Subject(s)
Hemorrhage/congenital , Adolescent , Adult , Female , Humans , Iran , Male , Young AdultABSTRACT
RasGRP2 is calcium and diacylglycerol-regulated guanine nucleotide exchange factor I that activates Rap1, which is an essential signaling-knot in "inside-out" αIIbß3 integrin activation in platelets. Inherited platelet function disorder caused by variants of RASGRP2 represents a new congenital bleeding disorder referred to as platelet-type bleeding disorder-18 (BDPLT18). We review here the structure of RasGRP2 and its functions in the pathophysiology of platelets and of the other cellular types that express it. We will also examine the different pathogenic variants reported so far as well as strategies for the diagnosis and management of patients with BDPLT18.
Subject(s)
Blood Platelet Disorders/genetics , Blood Platelets/pathology , Guanine Nucleotide Exchange Factors/genetics , Hemorrhage/genetics , Blood Platelet Disorders/congenital , Child, Preschool , Female , Guanine Nucleotide Exchange Factors/metabolism , Hemorrhage/congenital , Humans , Infant , Male , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Shelterin Complex , Signal Transduction/genetics , Telomere-Binding Proteins/metabolismABSTRACT
Perinatal pulmonary hemorrhage (PH) is a condition characterized by blood loss via the respiratory tract with an approximate incidence of 0.1% in all newborns. The histologic characteristics of the lung in PH are not well characterized, and we hypothesized that pulmonary maldevelopment such as pulmonary hypoplasia may contribute to PH. In addition, we sought to find any correlations with placental pathology. Retrospective study of fetal and neonatal autopsies with diagnosis of PH was performed between the years from 2009 to 2015. Autopsy reports, placental pathology reports, and hematoxylin and eosin sections of the lung were reviewed. Of the 17 cases which were identified meeting inclusion criteria, PH ranged from mild (<5% in each lung) to severe (>75% in both lungs). PH involved >50% of both lungs in 6 cases. Pulmonary hypoplasia was designated in 7 of 17 (41.17%) cases with PH. Pulmonary hypoplasia and/or persistence of intra-acinar arterioles was seen in 13 of 17 (76.4%) cases. No specific placental pathology was seen universally in the cases of PH, but either maternal or fetal vascular malperfusion was noted in 14 of 17 (82%) cases. Our data suggest a high prevalence of pulmonary maldevelopment, such as pulmonary hypoplasia and persistence of intra-acinar arterioles, in cases with PH. Although no specific placental pathology is seen in PH, maternal and fetal vascular pathology is common.
Subject(s)
Hemorrhage/pathology , Lung Diseases/pathology , Lung/pathology , Placenta Diseases/pathology , Placenta/pathology , Abnormalities, Multiple/diagnosis , Abnormalities, Multiple/pathology , Autopsy , Female , Hemorrhage/congenital , Hemorrhage/diagnosis , Hemorrhage/embryology , Humans , Infant, Newborn , Lung/abnormalities , Lung/blood supply , Lung/embryology , Lung Diseases/congenital , Lung Diseases/diagnosis , Lung Diseases/embryology , Male , Placenta Diseases/epidemiology , Pregnancy , Prevalence , Retrospective StudiesABSTRACT
Congenital factor VII deficiency is a rare autosomal recessive disorder associated to different haemorrhagic manifestations. Labour and delivery may cause bleeding risk in patients with this coagulation deficit, thus it is appropriate to clarify whether prophylaxis of peripartum haemorrhage is necessary. To date, there are very few cases in scientific literature which report the management of women with congenital factor VII deficiency during labour, and a consensus for prophylaxis does not exist. In this manuscript we present the management of a 35 years old woman with factor VII deficiency, treated with recombinant factor VIIa before delivery, without haemorrhagic complications either for the woman and for the infant. Therefore, we present a review of similar cases managed with a peripartum prophylaxis with recombinant factor VIIa, and discuss its usefulness and effectiveness, in view of the severity of the deficit and the doses used.
Subject(s)
Factor VII Deficiency/drug therapy , Factor VIIa/therapeutic use , Hemorrhage/prevention & control , Pregnancy Complications, Hematologic/drug therapy , Pregnancy Complications, Hematologic/prevention & control , Adult , Factor VII Deficiency/congenital , Female , Hemorrhage/congenital , Humans , Peripartum Period , Pregnancy , Recombinant Proteins/therapeutic useABSTRACT
Essentials A novel fibrinogen concentrate was evaluated in patients with congenital fibrinogen deficiency. An open-label, phase 2-3 trial studied pharmacology, efficacy, and safety in patients >6 years. The product offers safe and effective therapy in the treatment and prophylaxis of bleeding. Data in recovery show the need of adjusted treatment and further investigation in children. SUMMARY: Background Single-factor replacement therapy is considered the most suitable treatment option for hereditary fibrinogen deficiency. A triple-secured plasma-derived human fibrinogen product was developed to increase the safety of the former fibrinogen concentrate. Objectives This non-randomized, open-label, prospective study investigated pharmacokinetics, efficacy, and safety of a novel fibrinogen concentrate (FibCLOT® /CLOTTAFACT® LFB, France) in inherited deficiency. Patients/Methods Fourteen patients ≥40 kg received fibrinogen concentrate for pharmacology and 16 ≥ 23 kg received treatment for bleeding or surgery. Each treatment was followed by a 3-week safety observation period. Key outcomes included number of infusions, dose, bleeding control, daily assessment, hemoglobin, blood loss, transfusions, and physicians' global assessment of response. Results Incremental recovery was 2.35 mg mL-1 per mg kg-1 and maximal concentration 1.41 g L-1 (geometric mean) after 0.060 g kg-1 infusion in 14 afibrinogenemic patients. Terminal half-life was 69.3 h (non-compartmental analysis). The maximum clot firmness was increased by a mean of 10.3 mm from baseline to maximal effect. Sixteen patients participated to the efficacy phase: 32 bleeding episodes were treated in 9 patients, and 15 patients underwent 38 surgical/invasive procedures. All patients achieved appropriate hemostasis: response to treatment was successful in all bleeds (95% CI, 0.89-1.00) and procedures (95% CI, 0.91-1.00). Most (94%) bleeds were controlled with a single infusion (median 0.050 g kg-1 ). Two patients experienced asymptomatic distal venous thromboses identified by systematic ultrasound. Conclusion FibCLOT® /CLOTTAFACT® showed a pharmacokinetic profile comparable to that of other fibrinogen concentrates and provides safe and clinically effective substitution therapy for fibrinogen-deficient patients.
Subject(s)
Afibrinogenemia/drug therapy , Fibrinogen/administration & dosage , Hemorrhage/drug therapy , Hemostasis/drug effects , Hemostatics/administration & dosage , Adolescent , Adult , Afibrinogenemia/blood , Afibrinogenemia/congenital , Afibrinogenemia/diagnosis , Age Factors , Child , Female , Fibrinogen/adverse effects , Fibrinogen/pharmacokinetics , Hemorrhage/blood , Hemorrhage/congenital , Hemorrhage/diagnosis , Hemostatics/adverse effects , Hemostatics/pharmacokinetics , Humans , Male , Prospective Studies , Treatment Outcome , Young AdultABSTRACT
Physical activity provides many benefits in patients with congenital bleeding disorders. Patients with hemophilia are encouraged to participate in exercise and sports, especially those patients receiving prophylaxis. Several publications and guidelines have explored this issue in hemophilia patients, evaluating in particular the impact of physical activity on patients' well-being and quality of life. The other rare congenital bleeding disorders are less studied; they are heterogeneous in terms of clinical bleeding phenotype, incidence of hemarthrosis, and arthropathy. Furthermore, prophylaxis in these patients is less common than in hemophilia patients, which must be considered when choosing the type of physical and sporting activity. In this review, the authors have analyzed the literature focusing their attention on those rare coagulation disorders that may be complicated by arthropathy and the role of exercise and sports in this context.
Subject(s)
Exercise/physiology , Hemorrhage/physiopathology , Quality of Life , Sports/physiology , Hemarthrosis/physiopathology , Hemarthrosis/prevention & control , Hemophilia A/physiopathology , Hemophilia A/prevention & control , Hemophilia B/physiopathology , Hemophilia B/prevention & control , Hemorrhage/congenital , Hemorrhage/prevention & control , HumansABSTRACT
Occult Hepatitis B Infection (OBI) is a form of chronic HBV infection characterized by low level HBV DNA, without detectable HBV surface antigen (HBsAg). OBI is frequently associated with the presence of anti-HBc and in some cases also with anti-HBs. Patients, who formerly received non-inactivated factor concentrates, can potentially be considered at high risk for OBI, especially since these patients usually are HIV or HCV co-infected. This study aimed to assess the prevalence of occult HBV infection in Greek patients with hereditary bleeding disorders. The study sample comprised of 114 patients from a single haemophilia center. All patients were screened for HBV serum markers and individually tested for HBV DNA using a qualitative PCR. Presence of HBV DNA was further confirmed by quantification of viral load with an ultrasensitive in-house real time PCR. 88 and 21 patients with haemophilia A and B, respectively, 4 patients with von Willebrand Disease and 1 patient with severe factor VII deficiency were screened for the presence of OBI. Anti-HBc were detected in 53 (46.5%) subjects; 18 of them were anti-HBs(-) and 35 anti-HBs(+). Anti-HBe were present in 26 subjects. Two out of 114 patients were HBsAg(+). Of the remaining 112 HBsAg(-) patients tested, two (1.8%) were found HBsAg(-), HBV DNA(+), anti-HBc(+) and anti-HBs(-) and were identified as potential OBI cases. Both cases exhibited very low DNA levels; 38.2IU/mL in patient A and 14.2IU/mL in patient B. Both patients were HBeAg(-), but patient A had HBe antibodies. Patient B was also HIV/HCV co-infected. In conclusion, two cases of OBI with low HBV viraemia were identified among patients with congenital bleeding disorders. Although the incidence in our sample is moderately low (1.8%), close monitoring of these infections is of great clinical significance, especially in patients with co-infections and concomitant immunosuppression.
Subject(s)
Hemorrhage/congenital , Hemorrhage/virology , Hepatitis B Antibodies/blood , Hepatitis B/diagnosis , Hepatitis B/epidemiology , Adult , Aged , DNA, Viral/analysis , DNA, Viral/blood , Female , Greece/epidemiology , Hemorrhage/blood , Hepatitis B/blood , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B e Antigens/immunology , Humans , Male , Middle Aged , Prevalence , Viral Load , Young AdultABSTRACT
BACKGROUND: Among these diseases, congenital bleeding disorders (CBD) represent a significant societal burden in terms of high morbidity costs and health outcomes. In Italy, the organization and provision of health care is a regional responsibility and regions must assure equity and quality to all their residents. This is also true for CBD care which is provided by 54 multidisciplinary Hemophilia Treatment Centers (HTCs) distributed among the regions. With the present study, we intend to stimulate a debate on the effect that the decentralization process have in the delivery of services to CBD patients across Italy. METHODS: The available comparable measures of caseloads per center and interregional patient mobility, as proxies of quality and responsiveness of the regional network of HTCs, were first analyzed for the using data from the Italian Hemophilia Centers Association for the year 2012. RESULTS: Nine thousand one hundred and thirty four Italian residents with CBD received care in at least one of the Italian HTC in 2012. Preliminary findings suggested room for improvement in health care delivery for CBD patients. In 2012, 16 HTCs out of 51 (31.4%) treated a number of patients under the minimum requirement for treatment center accreditation (10 severe patients). Moreover, data on interregional patient mobility highlighted differences in the ability of each region to retain its own residents or to attract residents from other regions. CONCLUSIONS: Preliminary study results showed significant disparities among regions in terms of volumes and mobility of residents with CBDs that cannot be completely explained by the different geographical characteristics. Therefore, the central government should consider taking concrete measures to bridge the gap between regions to assure access to quality care for all individuals with CBD independently from where they live and therefore to move toward a more integrated and homogeneous national network of care centers. Typology of disease, patients' needs, and cost for outcomes, should have high priority on the political agenda. For CBD patients, even in a federal healthcare system, the national government should have the global responsibility to guaranteeing uniform levels of quality care over the country and overcome local institutions when necessary.
Subject(s)
Hemorrhage/congenital , Hemorrhage/epidemiology , Models, Biological , Geography , Hemophilia A/epidemiology , Humans , Italy/epidemiologySubject(s)
Blood Coagulation Disorders, Inherited/genetics , Blood Platelet Disorders/genetics , Blood Platelets/metabolism , Core Binding Factor Alpha 2 Subunit/genetics , Hemorrhage/genetics , Leukemia, Myeloid, Acute/genetics , Mutation , RNA, Messenger/genetics , Blood Coagulation Disorders, Inherited/pathology , Blood Platelet Disorders/pathology , Blood Platelets/pathology , Chromosomes, Human, Pair 21/chemistry , Gene Expression , Genes, Dominant , Hemorrhage/congenital , Hemorrhage/physiopathology , Humans , Leukemia, Myeloid, Acute/pathology , Platelet Count , Protein DomainsABSTRACT
The diagnosis of congenital and acquired bleeding disorders in infants requires an understanding of developmental haemostasis and the effect on laboratory testing. A systematic approach to bleeding in neonates will aid clinicians in the diagnosis and treatment, which may be caused by a wide variety of diseases. The clinical setting will help to direct the diagnostic pathway. This review will focus on the presentation and diagnosis of congenital and acquired bleeding disorders, including platelet disorders. Current research in this field is ongoing, including investigation into neonatal platelets and their different functionalities, platelet transfusion thresholds and how changes in coagulation factors may be linked to other homeostatic mechanisms.
Subject(s)
Blood Coagulation Disorders/congenital , Hemorrhage/congenital , Blood Coagulation Disorders/blood , Blood Coagulation Disorders/therapy , Blood Coagulation Factors/therapeutic use , Blood Platelet Disorders/blood , Blood Platelet Disorders/congenital , Blood Platelet Disorders/therapy , Blood Platelets/pathology , Blood Platelets/physiology , Hemorrhage/blood , Hemorrhage/therapy , Hemostasis/physiology , Humans , Infant , Infant, Newborn , Infant, Newborn, Diseases/blood , Infant, Newborn, Diseases/etiology , Infant, Newborn, Diseases/therapy , Thrombocytopenia/blood , Thrombocytopenia/complications , Thrombocytopenia/congenital , Thrombocytopenia/therapyABSTRACT
The presentation of a neonate with clinical bleeding symptoms commonly causes considerable anxiety to parents and treating physicians. Since inherited coagulation disorders are rare many children with persistently abnormal coagulation screens will have an underlying bleeding disorder. Apart from emergency cases a family history including a bleeding questionnaire is mandatory asking for the onset and/or severity symptoms of hemorrhage prior to laboratory assessment. The absolute values of reference ranges for coagulation assays in neonates and children vary with analyzer and reagent systems, but confirm the concept of developmental hemostasis, showing that physiologic concentrations of coagulation proteins gradually increase and are lower in premature infants as compared to full-term babies or healthy children. The evaluation should include global screening tests and a full blood cell count to rule out thrombocytopenia. As in adults a prolonged PT in neonates reflects decreased plasma concentrations of vitamin-K-dependent factors, whereas the prolonged PTT stems from decreased plasma levels of contact factors. When initial laboratory test results reveal abnormalities, as compared to age-related values, a stepwise diagnostic approach should be followed. In the bleeding neonate or infant that has no laboratory abnormality, FXIII and alpha2-antiplasmin activity should be assessed, and when primary hemostatic defects are suspected, platelet function should be further evaluated. Treatment options of a bleeding neonate vary according to the underlying medical condition.
Subject(s)
Antifibrinolytic Agents/therapeutic use , Blood Coagulation Tests/methods , Hemorrhage/diagnosis , Hemorrhage/therapy , Physical Examination/methods , Vitamin K/therapeutic use , Hemorrhage/congenital , Humans , Infant , Infant, NewbornABSTRACT
Inherited disorders of platelet function are a heterogeneous group. For optimal prevention and management of bleeding, classification and diagnosis of the underlying defect are highly recommended. An interdisciplinary guideline for a diagnostic approach has been published (AWMF # 086-003 S2K; Hämostaseologie 2014; 34: 201-212). Underlying platelet disorder, platelet count, age and clinical situation modify treatment. Exclusive transfusion of platelet concentrates may be inappropriate as potentially adverse effects can outweigh its benefit. A stepwise and individually adjusted approach for restitution and maintenance of haemostasis is recommended. Administration of antifibrinolytics is generally endorsed, but is of particular use in Quebec disease. Restricted to older children, desmopressin is favourable in storage pool disease and unclassified platelet disorders. Although licensed only for patients with Glanzmann thrombasthenia and alloantibodies, in clinical practice rFVIIa is widely used in inherited platelet disorders with severe bleeding tendency. This guideline aims at presenting the best available advice for the management of patients with inherited platelet function disorders.
Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Blood Platelet Disorders/congenital , Blood Platelet Disorders/therapy , Deamino Arginine Vasopressin/therapeutic use , Factor VIIa/therapeutic use , Hemorrhage/therapy , Platelet Transfusion/standards , Anti-Arrhythmia Agents/standards , Blood Platelet Disorders/diagnosis , Child , Child, Preschool , Female , Germany , Hematology/standards , Hemorrhage/congenital , Hemorrhage/diagnosis , Hemostatics/therapeutic use , Humans , Infant , Infant, Newborn , Male , Pediatrics/standards , Practice Guidelines as TopicABSTRACT
We report on the case of a 15-year-old boy with massive hemoptysis caused by anastomosis between bronchial and pulmonary arteries, successfully treated with embolization. No similar case was found in the literature, likely because of the high mortality rate of this type of malformation.
Subject(s)
Arterio-Arterial Fistula/congenital , Bronchial Arteries/abnormalities , Hemoptysis/etiology , Pulmonary Artery/abnormalities , Adolescent , Angiography , Arterio-Arterial Fistula/diagnosis , Arterio-Arterial Fistula/therapy , Bronchoscopy , Embolization, Therapeutic , Hemoptysis/therapy , Hemorrhage/congenital , Hemorrhage/diagnosis , Hemorrhage/therapy , Humans , Lung Diseases/congenital , Lung Diseases/diagnosis , Lung Diseases/therapy , Male , Pulmonary Alveoli/pathologyABSTRACT
What is the correct use of established clotting factors, prothrombin complex concentrates (PCCs), and activated factor VII in bleeding complications of trauma, surgery, and old and new oral anticoagulants? How will new clotting factors, specifically the long-acting factors, change the hemostatic management of coagulation deficiency disorders? From bench to bedside, comparative coagulation studies and clinical trials of modified clotting factors are providing insights to help guide hemostatic management of congenital and acquired bleeding disorders. Comparative thrombin-generation studies and preclinical and clinical trials suggest that PCCs and fresh-frozen plasma are effective in reversing the anticoagulant effects of warfarin, yet there are few data to guide reversal of the new oral anticoagulants dabigatran and rivaroxaban. Although coagulation studies support the use of PCCs to reverse new oral anticoagulants, correlation with clinical response is variable and clinical trials in bleeding patients are needed. For congenital bleeding disorders, exciting new technologies are emerging from the bench. Data from clinical trials of molecularly modified coagulation factors with extended half-lives suggest the possibility of fewer infusions, reduced bleeds, and better quality of life in persons with hemophilia. Preclinical studies of other novel prohemostatic approaches for hemophilia and other congenital coagulation disorders include RNA interference silencing of antithrombin, monoclonal anti-tissue factor pathway inhibitor (anti-antibody, anti-tissue factor pathway inhibitor) aptamer, bispecific anti-IXa/X antibody, and fucoidans. Understanding the comparative coagulation studies of established prohemostatic agents, the pharmacokinetics of new long-acting clotting factors, and their correlation with bleeding outcomes will provide opportunities to optimize the hemostatic management of both congenital and acquired hemostatic disorders.
Subject(s)
Anticoagulants/therapeutic use , Blood Coagulation Factors/therapeutic use , Factor VIIa/therapeutic use , Hemophilia A/drug therapy , Hemorrhage/drug therapy , Hemostatics/therapeutic use , Antibodies/therapeutic use , Anticoagulants/pharmacokinetics , Benzimidazoles/pharmacokinetics , Benzimidazoles/therapeutic use , Blood Coagulation Factors/pharmacokinetics , Clinical Trials as Topic , Dabigatran , Factor VIIa/pharmacokinetics , Female , Half-Life , Hemorrhage/congenital , Hemostatics/pharmacokinetics , Humans , Male , Morpholines/pharmacokinetics , Morpholines/therapeutic use , RNA Interference , Rivaroxaban , Thiophenes/pharmacokinetics , Thiophenes/therapeutic use , beta-Alanine/analogs & derivatives , beta-Alanine/pharmacokinetics , beta-Alanine/therapeutic useABSTRACT
Klippel-Trenaunay syndrome (KTS) is an uncommon congenital angiodysplasia that manifests in infancy and is characterized by venous and lymphatic malformations of the skin, soft tissue, and bone causing limb hypertrophy. We report 2 patients with long-term KTS who developed lethal complications from uncommon and unusual manifestations. The 1st patient was a female with KTS who at 2 years of age underwent a below-the-knee amputation for a massively hypertrophied and malformed left foot. Two years later she required additional surgical removal of vascular malformations involving her left calf with extension to the groin, pubis, and ipsilateral abdomen. Fifteen years later she underwent splenectomy (400 g) revealing multifocal, cystically dilated vascular channels distorting the splenic architecture and died suddenly of massive intra-abdominal hemorrhage on the 2nd postoperative day. The 2nd patient was a 72-year-old male with long-standing KTS who presented with debilitating chronic penile and scrotal edema. Surgical excision of his lymphedematous scrotal and penile skin revealed a low-grade angiosarcoma arising in the setting of chronic lymphedema. The patient died shortly after surgery from massive hemorrhage due to traumatic rupture of malformed leg vessels. KTS may lead to significant morbidity and mortality, and pathologic consequences from long-term KTS have been rarely reported. These cases illustrate the risk of lethal hemorrhage, organomegaly from protracted vascular malformation, and development of vascular neoplasia associated with chronic lymphedema in KTS.
Subject(s)
Hemorrhage/etiology , Klippel-Trenaunay-Weber Syndrome/complications , Klippel-Trenaunay-Weber Syndrome/pathology , Adolescent , Age of Onset , Aged , Child, Preschool , Fatal Outcome , Female , Hemorrhage/congenital , Humans , Klippel-Trenaunay-Weber Syndrome/physiopathology , MaleABSTRACT
El descubrimiento de los anticoagulantes se inició en 1916 con la aparición de la heparina, en 1941 se aisló y caracterizo el 3,3-metilenobis-(4-hidroxicumarina), que más tarde se conocería como dicumarol o bishidroxicumarina. El desarrollo de los nuevos anticoagulantes orales ha sido lento hasta la reciente introducción de dabigatrán, un inhibidor oral de trombina, y rivaroxabán, inhibidor oral del factor Xa. La heparina presenta una serie de inconvenientes, como la necesidad de administración parenteral, complicaciones hemorrágicas al inducir trombocitopenia, osteoporosis, reacciones cutáneas, reacciones de hipersensibilidad y elevación de las transaminasas. Los antagonistas de la vitamina K tienen un mecanismo de acción indirecto, presentan múltiples interacciones con fármacos y alimentos, dificultad de dosificación y precisan la monitorización de su efecto. Las limitaciones de los actuales fármacos antitrombóticos ha impulsado la búsqueda de nuevos agentes, que para superar las limitaciones de los AVK deben reunir, entre otras, las siguientes características: administración oral, bajo riesgo de hemorragia, una cinética predecible, que no requieran vigilancia de la coagulación, que no sea necesario ajustar la dosis y tener una baja interacción con fármacos y alimentos (AU)
The discovery of anticoagulants started in 1916 with the finding of heparin; in 1941 3,3-metilenobis-(4-hidroxicumarin) was isolated and characterized, and would later become known as dicumarol or bishydroxycoumarin. The development of the new oral anticoagulants was slow until the recent introduction of dabigatran, a novel oral thrombin inhibitor, and rivaroxaban, an oral factor Xa (FXa) inhibitor-Heparin has a series of disadvantages, such as the need for parenteral administration, hemorrhagic complications if thrombocytopenia develops, osteoporosis, cutaneous reactions, hypersensitivity reactions, and transaminase elevation. In addition, monitoring is required. Vitamin K antagonists also require monitoring and have an indirect mechanism of action and multiple food and drug interactions. Dosing is also problematic. The limitations of currently available antithrombotic agents have prompted the search for new drugs. To overcome the limitations of VKA, these drugs should include the following characteristics, among others; oral administration, low bleeding risk, predictable kinetics, few food and drug interactions and no requirement for dose adjustments. (AU)
Subject(s)
Female , Humans , Male , Heparin/administration & dosage , Dicumarol , Dicumarol/metabolism , Hemorrhage/congenital , Hemorrhage/complications , Patients/classification , Blood Coagulation/physiology , Heparin/pharmacology , Dicumarol/administration & dosage , Dicumarol/supply & distribution , Hemorrhage/genetics , Hemorrhage/pathology , Patients/legislation & jurisprudenceABSTRACT
Fibrosarcomas are rare malignant soft-tissue tumors occurring mostly in infants younger than 1 year of age. Fibrosarcomas can ulcerate and cause various complications, which could threaten a fetus in utero or a child in the early neonatal period. We report a unique case of congenital infantile fibrosarcoma of the lower leg, its treatment and pathology. The large expansive and destructive lesion was not appreciated on routine prenatal ultrasound exams at 20 and 33 weeks gestation. The newborn required immediate emergency surgical intervention after delivery to prevent death by hemorrhagic shock. Initial debulking of the tumor was performed and hemostasis was attained on the day of birth. The child was resuscitated and definitive treatment of the leg was deferred until a pathologic diagnosis was obtained. Given the extent of the fibrosarcoma, the lower leg was not salvageable and the patient received a through-the-knee amputation in the neonatal period. The patient is free of disease at 2 years of age.
Subject(s)
Fibrosarcoma/congenital , Fibrosarcoma/surgery , Hemorrhage/surgery , Skin Ulcer/surgery , Soft Tissue Neoplasms/congenital , Soft Tissue Neoplasms/surgery , Emergencies , Fibrosarcoma/pathology , Follow-Up Studies , Hemorrhage/congenital , Hemorrhage/pathology , Humans , Infant, Newborn , Intensive Care Units, Neonatal , Lower Extremity/pathology , Lower Extremity/surgery , Male , Rare Diseases , Risk Assessment , Skin Ulcer/congenital , Skin Ulcer/pathology , Soft Tissue Neoplasms/pathology , Treatment OutcomeABSTRACT
Congenital abnormalities of platelet function disorder (PFD) are associated with the heightened risk for bleeding. Typically, patients with PFDs have mucocutaneous bleeding of variable severity and excessive hemorrhage after surgery or trauma. The diagnostic laboratory assessment appropriate for the evaluation of suspected inherited PFD should be based on a two-step diagnostic strategy: the first step, based on screening tests, helps raising a diagnostic hypothesis, which should then be tested in the second step, which is based on the use of specific tests. The first step should include: complete blood cell count, examination of the peripheral blood smear, and assessment of platelet aggregation. Although light transmission aggregometry (LTA) is the most widely used platelet function test, it is relatively insensitive to defects of platelet secretion; for this reason, laboratory tests that measure platelet aggregation and secretion simultaneously, such as lumi-aggregometry, should be preferred to traditional LTA. The second step includes specific tests (e.g., flow cytometry, Western blotting, DNA analysis). Platelet transfusions should be used only to treat severe bleeding episodes. Recombinant Factor VIIa can be used in patients with severe bleeding episodes who do not respond to platelet transfusion because of alloimmunization. Fibrinolytic inhibitors or the vasopressin analogue desmopressin (DDAVP) should be used in all other circumstances.
Subject(s)
Blood Platelet Disorders/diagnosis , Blood Platelet Disorders/therapy , Deamino Arginine Vasopressin/therapeutic use , Factor VIIa/therapeutic use , Hemorrhage/diagnosis , Hemorrhage/therapy , Hemostatics/therapeutic use , Blood Cell Count , Blood Platelet Disorders/complications , Blood Platelet Disorders/congenital , Blood Platelets/drug effects , Blood Platelets/physiology , Blotting, Western , Flow Cytometry , Hemorrhage/complications , Hemorrhage/congenital , Humans , Platelet Aggregation/drug effects , Platelet Function Tests , Platelet Transfusion , Recombinant Proteins/therapeutic use , Sequence Analysis, DNAABSTRACT
Neonatal thrombocytopenia is one of the most common hematologic disorders in neonatal intensive care units (NICUs). The purpose of this study was to determine the prevalence of thrombocytopenia and whether thrombocytopenia has an effect on the occurrence of intraventricular hemorrhage (IVH) ≥ grade 2 and on mortality rate. This study was carried out retrospectively in neonates admitted to NICU of Cumhuriyet University in Sivas, Turkey, between 2009 and 2012. Among 2218 neonates evaluated, 208 (9.4%) developed thrombocytopenia. The prevalence of IVH ≥ grade 2 was more in infants with thrombocytopenia (7.2%) than in those without thrombocytopenia (4.4%), although this was not statistically significant (P = .08). In univariate analysis, IVH ≥ grade 2 was higher in cases with very severe thrombocytopenia (35.7%, n = 5) than in those with mild (2.1%, n = 2), moderate (4.7%, n = 3), and severe thrombocytopenia (15.2%, n = 5) (P = .04). Multivariate logistic regression analysis showed that birth weight <1500 g (OR 6.2, 95% CI 3.4-9.8; P = .0001), gram-negative sepsis (OR 2.5, 95% CI 1.8-4.2; P = .01), very severe thrombocytopenia (OR 1.3, 95% CI 1.1-2.1; P = .03), and platelet transfusion ≥2 (OR 7.3, 95% CI 4.1-12.1; P = .001) were significant risk factors for mortality. The results of our study suggest that outcomes of neonates with thrombocytopenia depend not only on platelet count but also on decreased gestational age or birth weight, prenatal factors, and sepsis.
Subject(s)
Infant, Newborn, Diseases/mortality , Thrombocytopenia/mortality , Birth Weight , Female , Hemorrhage/blood , Hemorrhage/congenital , Hemorrhage/mortality , Hemorrhage/therapy , Humans , Infant, Newborn , Infant, Newborn, Diseases/blood , Infant, Newborn, Diseases/therapy , Intensive Care Units, Neonatal , Male , Platelet Count , Platelet Transfusion , Prevalence , Retrospective Studies , Risk Factors , Thrombocytopenia/blood , Thrombocytopenia/congenital , Thrombocytopenia/therapy , Turkey/epidemiologyABSTRACT
INTRODUCTION: Evidence-based guidelines for the management of acute coronary syndrome (ACS) in patients with congenital bleeding disorders are lacking and largely confined to case reports. METHODS: Outcomes of acute and long-term management of ACS in patients with mild hemophilia and von Willebrand disease managed at our institution from 2000-2011 were reviewed. RESULTS: Between 2000-2011, 8 patients (median age 74 years) experienced 10 ACS events. In the emergency room, 3 of 4 patients received aspirin 325 mg and intravenous unfractionated heparin therapy, with no acute bleeding complications. The 8 patients underwent 10 coronary angiography procedures. Prophylactic factor concentrates were not administered for 6/10 (60%) of the procedures; bleeding complications (groin hematoma) occurred in 1/6 (17%). Two patients receiving bare metal stents and glycoprotein IIb/IIIa inhibitor infusion with factor concentrates experienced no acute hemorrhagic complications. On discharge, aspirin was initiated/continued in 6/10 events; the 2 patients receiving dual anti-platelet therapy for 1 month did not receive factor concentrates and experienced no bleeding complications. During a median follow-up of 8.5 years (1 - 11.5 years), 2 of 5 patients developed minor bleeding complications while on aspirin. CONCLUSION: Our data demonstrate that in patients with mild congenital bleeding disorders, despite not receiving factor concentrates prior to coronary angiography, the acute management of ACS did not result in severe hemorrhagic complications. Short-term dual anti-platelet therapy seemed to be well tolerated. In patients receiving long-term aspirin for secondary prevention for ACS, bleeding complications were mild, however such patients warrant close follow-up.